Healthcare systems worldwide are grappling with escalating costs, a growing elderly population requiring polypharmacy, and increasing regulatory scrutiny on drug safety. There's a critical need for solutions that enhance diagnostic precision and operational efficiency while mitigating human error. This technology aligns perfectly with the global shift towards data-driven medicine and AI integration, offering a vital tool to improve patient outcomes and reduce healthcare expenditures by an estimated ~$1.0M per facility annually.
Improves diagnostic accuracy by up to 3x by objectively estimating culprit drugs in polypharmacy environments, surpassing traditional methods.
Reduces adverse reaction estimation time by 80% through automated data acquisition and probability calculation, enabling faster treatment decisions.
Ensures market advantage with robust IP protection until ~2042, having successfully navigated rigorous examination and prior art challenges.
This patent protects a system, program, and method for estimating suspected adverse drug reactions, covering a broad scope with 10 claims. Its robustness is evidenced by successfully overcoming examiner objections during prosecution, ensuring a stable and defensible right for licensees.
This patent focuses on post-reaction culprit drug estimation. White space exists in developing proactive AI systems for personalized drug regimen optimization or integrating with real-time patient monitoring devices for predictive adverse event alerts.
This technology could mitigate extended hospital stays and additional treatments due to adverse reactions. For instance, if adverse reaction-related hospital stays are shortened by an average of 5 days, an annual medical cost reduction of ~$2,000 per patient (AI est.) is projected. Applied to 500 patients annually: 500 patients × ~$2,000/patient = ~$1.0M annual medical cost reduction (AI est.).
X: Diagnostic Accuracy (Objectivity)
Y: Ease of Implementation (Speed)